Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma

NCT04073147 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped low recruitment

Conditions

Primary CNS Lymphoma

Interventions

DRUG: Venetoclax
DRUG: Obinutuzumab

Sponsor

Klinikum Stuttgart

Collaborators

[object Object]